News: AMAG Pharmaceuticals Inc (AMAG.OQ)
AMAG.OQ on NASDAQ Stock Exchange Global Select Market
23.61USD
1 Aug 2013
23.61USD
1 Aug 2013
Price Change (% chg)
$1.11 (+4.93%)
$1.11 (+4.93%)
Prev Close
$22.50
$22.50
Open
$23.15
$23.15
Day's High
$23.72
$23.72
Day's Low
$22.92
$22.92
Volume
22,309
22,309
Avg. Vol
36,596
36,596
52-wk High
$25.63
$25.63
52-wk Low
$13.90
$13.90
Select another date:
Tue, May 21 2013
CORRECTED-Amag investigates anemia drug after report of death in Switzerland
(Corrects headline to "investigates." Amag did not say the drug caused the fatality.)
Amag says anemia drug caused fatal reaction in Switzerland
- Amag Pharmaceuticals Inc said its marketing partner in Switzerland, Takeda Pharmaceutical Co Ltd, is recalling a batch of Amag's anemia drug, Rienso, because of a death and several cases of hypersensitivity.
Amag says anemia drug caused fatal reaction in Switzerland
May 21 - Amag Pharmaceuticals Inc said its marketing partner in Switzerland, Takeda Pharmaceutical Co Ltd, is recalling a batch of Amag's anemia drug, Rienso, because of a death and several cases of hypersensitivity.
Austria's B&C makes 23.40 eur takeover offer for AMAG
FRANKFURT, March 11 - Austrian investment group B&C Industrieholding GmbH said it will make a mandatory takeover offer of 23.40 euros to shareholders in aluminium group AMAG .
Select another date:
- Keryx Biopharmaceuticals Presents An Attractive Investment Opportunity
- FDA Decisions: Interesting Biotechnology Catalyst Events
- Solid Showing At WCN Conference For Keryx: Catalysts Still To Come
- Keryx: Attractive In Front Of Catalyst-Rich Second Half
- 3 Horrendous Health-Care Stocks This Week
- A Review Of Upcoming Catalysts For Kidney Disease Biotech Players In 2013
Press Releases
- AMAG Pharmaceuticals Announces New Data from Ferumoxytol Pivotal Phase III Broad Iron Deficiency Anemia Program Presented at ASH
- AMAG Pharmaceuticals, Inc. to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
- AMAG Pharmaceuticals, Inc. Announces that Feraheme Abstracts for the American Society of Hematology Annual Meeting are Now Available
- Rienso (Ferumoxytol) Launched in Europe for the Treatment of Iron Deficiency Anemia in Adult Patients with Chronic Kidney Disease
- AMAG Pharmaceuticals Announces Financial Results for the Third Quarter and Nine Months Ended September 30, 2012
- AMAG Pharmaceuticals, Inc. to Host Conference Call on November 1, 2012 at 8:00 a.m. ET to Discuss Financial Results for the Quarter Ended September 30, 2012
- Rienso® (Ferumoxytol) Receives Swiss Marketing Authorization for the Treatment of Iron Deficiency Anemia in Adult Patients with Chronic Kidney Disease
- AMAG Pharmaceuticals, Inc. to Participate in Upcoming Investor Conferences
- AMAG Pharmaceuticals, Inc. to Host Conference Call on July 26, 2012 at 8:00 a.m. ET to Discuss Financial Results for the Quarter Ended June 30, 2012
- AMAG Pharmaceuticals Announces Positive Preliminary Results from its Phase III Study Evaluating Feraheme Compared to Placebo in Patients with Iron Deficiency Anemia

